Abstracts tagged "immunology"

Abstract Number: 0747 • ACR Convergence 2025
Patterns of Macrophage Polarization Induced by Serum from Patients with Giant Cell Arteritis and Takayasu’s Arteritis
Irene Carrión-Barberà¹, Ryan D. Stultz², David Cuthbertson³, Nader Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Kenneth Warrington¹², Peter Merkel⁷ and Christian Lood¹³, ¹Department of Rheumatology. Hospital del Mar, Barcelona, Spain, ²University of Washington, Division of Rheumatology, Seattle, WA, ³University of South Florida, Tampa, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Pennsylvania, Philadelphia, PA, ⁸VA Boston Healthcare System, Boston, MA, ⁹University of Colorado, Denver, CO, ¹⁰Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, ROCHESTER, MN, ¹³University of Washington, Division of Rheumatology, Seattle
Background/Purpose: Macrophages play a central role in the pathogenesis of large-vessel vasculitides, including giant cell arteritis (GCA) and Takayasu’s arteritis (TAK). Characterizing patterns of macrophage…
Abstract Number: 2641 • ACR Convergence 2025
Cizutamig, a BCMA T-cell engager: preclinical to clinical translation of design optimization for the treatment of autoimmune diseases
Ricardo Grieshaber-Bouyer¹, Jamie Haddon², Maria Gabriella Raimondo³, Carlo Tur³, Sebastian Böltz³, Tobias Dashi⁴, Melanie Hagen⁵, Andreas Wirsching³, Tobias Rathe⁴, Xuan Wu⁶, Peter Wung², Francis Kim², Yonghong Zhu⁶, Ken Song², Timothy Lu⁷ and Georg Schett⁸, ¹University Hospital Erlangen, Erlangen, Germany, ²Candid Therapeutics, San Diego, CA, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine ³- Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁵Friedrich-Alexander-University Erlangen-Nuremberg, Department of Internal Medicine ³ - Rheumatology and Immunology, Erlangen, Germany, ⁶EpimAb Biotherapeutics, Shanghai, China (People's Republic), ⁷Candid Therapeutics, San Diego, ⁸Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: Emerging data show the potential of T-cell engagers (TCEs) for deep B cell depletion to treat autoimmune diseases. Cizutamig is a purposefully designed BCMAxCD3…
Abstract Number: 2152 • ACR Convergence 2025
Blau Syndrome: features beyond the classic triad and proposal for clinical criteria
Narendra Bagri¹, Nawazish Shaikh², Manisha jana³, Sushain kalsotra⁴, Krithika Rajkumar², Madhumita Roy Chowdhury², Neerja Gupta², Danveer Bhadu⁵, Vishal Gupta² and Rohan Chawla², ¹All India Institute of Medical Sciences(AIIMS), New Delhi, Delhi, India, ²All India Institute of Medical Sciences, Delhi, Delhi, India, ³ALL INDIA INSTITUTE OF MEDICAL SCIENCES, Delhi, ⁴All India Institute of Medical Sciences, Delhi, India, ⁵All India Institute of Medical Sciences, New Delhi, New Delhi, Delhi, India
Background/Purpose: This study describes the characteristic clinical and radiological findings and outcomes of patients with Blau syndrome from a single tertiary care hospital.Methods: A retrospective…
Abstract Number: 1741 • ACR Convergence 2025
Chronic JDM Plasma Proteomic Signature Reflects Inflammation from Immune and Tissue-resident Muscle and Skin
Marianne Kerski¹, Celine Berthier¹, Benjamin Klein¹, Li Chen², Christine Goudsmit², Sophia Matossian¹, Qinmengge Li³, Chioma Madubata⁴, Jessica Neely⁵, J. Michelle Kahlenberg¹ and Jessica Turnier⁶, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³University of Michigan, Ypsilanti, MI, ⁴UCSF, SF, CA, ⁵UCSF, San Francisco, CA, ⁶University of Michigan, Saline, MI
Background/Purpose: Juvenile dermatomyositis (JDM) and childhood-onset SLE (cSLE) are systemic autoimmune diseases characterized by overlapping yet distinct clinical manifestations and treatment responses. In this study,…
Abstract Number: 1251 • ACR Convergence 2025
Steroids and Me (Sam): engaging and educating steroid-treated patients via patient advocacy partnerships and internet search channels.
Michelle Petri¹, Martha Stone², John Stone³, meredith Marinaro⁴, Matt Wilkinson⁵, Walter Lentfert⁶, Camille Kotton⁷, Jeffrey Gelfand⁸, Jane McDowell⁹ and Tricha Shivas¹⁰, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Steritas, LLC, Concord, MA, ³Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁴Novartis, Hartford, CT, ⁵UpThereEverywhere, London, United Kingdom, ⁶UpThereEverywhere, Charlotte, NC, ⁷Harvard Medical School, Boston, MA, ⁸UCSF Department of Neurology, Mill Valley, CA, ⁹Queens University Belfast, Belfast, United Kingdom, ¹⁰Foundation for Sarcoidosis Research, Chicago, IL
Background/Purpose: We report on two years of engagement with Sam, a patient-facing program to optimize the use of glucocorticoids and discontinue them when possible. We…
Abstract Number: 1001 • ACR Convergence 2025
LBL-057, a Novel ADCC Enhanced PD-1 Agonist VHH-Fc Antibody
Hongyan Shang¹, Xiao Huang², Duqing Jiang¹, Jianming Sun², Yurong Qin², Guojin Wu², Chengze Ni¹, Jing Guan², Jordan Zhu³, Xiaoqiang Kang² and Hong Ling², ¹Nanjing Leads Biolabs Co., Ltd., nanjing, China (People's Republic), ²Nanjing Leads Biolabs Co., Ltd., Nan Jing, China (People's Republic), ³Nanjing Leads Biolabs Co., Ltd., Nan Jing
Background/Purpose: Programmed cell death protein 1 (PD-1) is expressed on activated T cells and serves as a key co-inhibitory checkpoint molecule in immune regulation. Aberrant…
Abstract Number: 0897 • ACR Convergence 2025
APECED Disease Reorganizes The B Cell Compartment Toward Alternatively Activated Subsets
william Galbavy, Hyunjin Kim, Brian Klotz, Marine Malbec, Carley Tasker, Eva Conde, Andrea Vecchione, Seblewongel Asrat, Benjamin Daniel, Weikeat Lim, Andre Limnander and Jamie Orengo, Regeneron, Tarrytown, NY
Background/Purpose: Autoimmune PolyEndocrinopathy Candidiasis Ectodermal Dystrophy (APECED) is a rare syndrome of multi-organ autoimmunity driven by the presence of self-reactive T cells and autoantibodies caused…
Abstract Number: 0301 • ACR Convergence 2025
Novel HMGCS1 Deficiency Expands Proinflammatory Monocytes and Cytotoxic Populations with Increased Cytokine Release
Sabrina Helmold Hait¹, Mary Maclean², Cindy Phung³, Gustaf wigerblad⁴, Iago Pinal Fernandez⁴, Carl Esperanzate⁵, hongying Wang⁵, Andrew Mammen⁶, willian Gahl⁵, Daniel L. Kastner⁷, Stefania Dell'orso⁴, Danica Novacic⁵, massimo Gadina⁴ and Ivona Aksentijevich⁸, ¹NIAMS/NIH, Bethesda, MD, ²NIH-NIAMS, Rockville, MD, ³National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS), Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁵National Human Genome research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, MD, ⁶NIH, Bethesda, MD, ⁷National Human Genome research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, ⁸¹⁰⁰, Bethesda, MD
Background/Purpose: The mevalonate (MVK) pathway synthesizes isoprenoids that mediate post-translational protein modifications via prenylation. Deficient protein prenylation due to decreased mevalonate kinase (MK) activity leads…
Abstract Number: 2601 • ACR Convergence 2025
Characterisation of immunometabolic reprogramming at the single cell level in patients with systemic lupus erythematosus and preclinical autoimmunity
Antonios Psarras¹, Sinibaldo Arocha², Liezel Tamon², David Ahern², Md Yuzaiful Md Yusof³, Ed Vital⁴ and Alexander Clarke⁵, ¹University of Oxford, Oxford, England, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³University of Leeds, Leeds, United Kingdom, ⁴University of Leeds, Leeds, England, United Kingdom, ⁵Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is characterised by innate immune activation and autoantibodies against nucleic self-antigens. The metabolic state of immune cells is emerging as…
Abstract Number: 2062 • ACR Convergence 2025
Immune Cell Signatures Associated with Disease Activity in Dermatomyositis Across Autoantibody Subtypes
Jeffrey Sagun¹, Melissa Leeolou¹, Nicholas Geraci², Andrew Bender³, Fatima Strand², David Fiorentino¹ and Kavita Sarin¹, ¹Department of Dermatology, Stanford University Medical Center, Stanford, CA, ²EMD Serono, Billerica, MA, ³AbbVie, Worcester, MA
Background/Purpose: Dermatomyositis (DM) is a heterogeneous multisystem autoimmune disease characterized by inflammation of the skin, muscle, and lung. Identifying the immune cells that drive disease…
Abstract Number: 1733 • ACR Convergence 2025
Risk factors for the development of immune checkpoint inhibitor-related adverse events, including rheumatology-related presentations
Adela Francis-Malave¹, Terri Laufer², Joshua Baker³, Kyra Sacksith⁴, Melissa Batson⁴ and Sokratis Apostolidis³, ¹University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, ²University of Pennsylvania, Bala Cynwyd, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania, Philadelphia
Background/Purpose: While immune-related adverse events (irAEs) are a commonly reported complication of immune checkpoint inhibitor (ICI) therapy, factors associated with their development remain poorly defined.…
Abstract Number: 1227 • ACR Convergence 2025
The Composition of Circulating Immune Cells is Associated with Nociplastic Pain in Patients with Rheumatoid Arthritis
Tyler Therron¹, Meghan Mayer², Cecilia Stumpf³, Gelis Galarcé Lugo⁴, Morgan Langereis⁵, Kathleen Aren⁶, Mary Carns⁵, Cally Mills⁵, Cheol Min Lee⁷, Vanessa Manada De Lobos², Carla Marie Cuda⁵, Yvonne Lee⁵ and Deborah Rachelle Winter⁸, ¹Northwestern Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern University, Elmhurst, IL, ⁴Northwestern University Feinberg School of Medicine, Zionsville, IN, ⁵Northwestern University, Chicago, IL, ⁶Northwestern University Division of Rheumatology, Chicago, IL, ⁷Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸Northwestern University, Skokie, IL
Background/Purpose: Over half of patients with RA report clinically meaningful pain, despite treatment with disease-modifying antirheumatic drugs (DMARDs). While joint inflammation is a known cause…
Abstract Number: 0997 • ACR Convergence 2025
Identification of Novel HLA Class II–Restricted Autoantigens in Scleroderma and Ulcerative Colitis Using TargetScan 
Olivia Pryor¹, Catalina Burbano², Nathaniel Bagge², Rutuja Kulkarni², Heather F. Jones², Livio Dukaj², Shoshana M.K. Bloom², Jackson Lirette², Rachel Lent², Prachi Dhanania², Nicole A. Ladd², Ryan Kritzer², Hana Husic², Shobitha Jillella², Candace R. Perullo², Jinyu Zhu², Teagan J. Parsons², Ira Jain², Rakshika Balasubramaniyam², Kenneth L. Jahan², Vivin Karthik², Alexander Cristofaro¹, Chandan K. Pavuluri², Jenna LaBelle², Laurie Barefoot², Shrikanta Chattopadhyay², Kim M. Cirelli², Mollie M. Jurewicz², Andrew P. Ferretti² and Cagan Gurer², ¹TScan Therapeutics, Waltham, ²TScan Therapeutics, Waltham, MA
Background/Purpose: Selective modulation of autoimmune responses through antigen-specific therapies represents a promising direction for improving treatment specificity and safety. Genetic associations with HLA class II…
Abstract Number: 0663 • ACR Convergence 2025
iPSC-Derived Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy
Parastoo Fazeli¹, Jennifer Medlin², Andrew BitMansour³, Debra Zack⁴, Rebecca Elstrom⁵, Bertha Villa⁵, Lilly Wong⁶, John Goulding⁷, Nicholas Brookhouser⁵, Trever Greene⁵, Cara Bickers⁵, Carol Wong⁵, Beatrice Ferguson⁵, Tom Lee⁵, Jode Goodridge⁵, Marie Hu⁸, Veronika Bachanova⁸, Jeffrey Miller⁹, Bahram Valamehr⁶, Matthew Lunning¹⁰ and Vaneet Sandhu⁵, ¹UMN, ST PAUL, MN, ²University of Nebraska Medical Center, Omaha, NE, ³Fate Therapeutics, Inc., San Carlos, CA, ⁴Fate Therapeutics, Inc., Solana Beach, CA, ⁵Fate Therapeutics, Inc., San Diego, ⁶Fate Therapeutics, Inc., San Diego, CA, ⁷Fate Therapeutics, San Diego, ⁸University of Minnesota, Minneapolis, ⁹University of Minnesota, Minneaspolis, MN, ¹⁰University of Nebraska, Omaha
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy shows promise in autoimmune disease. However, autologous CAR T-cell therapy is limited by prolonged pre- and…
Abstract Number: 0296 • ACR Convergence 2025
Aggregation of HARS1 and internalized antibodies in muscle biopsies of patients with antisynthetase syndrome and anti-Jo1(HARS) autoantibodies
maria Casal-Dominguez¹, Iago Pinal Fernandez², Katherine Pak², Travis Kinder¹, Jon Musai¹, Ana Matas-Garcia³, Gloria Garrabou⁴, Iban aldecoa⁵, Albert Selva-O´callaghan⁶, José Milisenda⁷ and Andrew Mammen⁸, ¹National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain., Barcelona, Spain, ⁴Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain., Barcelona, ⁵Pathology, Neurological Tissue Bank. Hospital Clinic of Barcelona-CDB-IDIBAPS/FCRB-University of Barcelona, Barcelona, Spain., Barcelona, ⁶Systemic Autoimmune Disease Section, Vall d'Hebron Institute of Research, Barcelona, Spain, Barcelona, ⁷Hospital Clinic de Barcelona, Barcelona, Spain, ⁸NIH, Bethesda, MD
Background/Purpose: Autoimmune inflammatory myopathies (IMs) comprise a diverse group of diseases that primarily affect the muscles and often involve the lungs, skin, and joints. Among…

« Previous Page
1
…
3
4
5
6
7
…
33
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].